- Home
- VERU
VERU
Veru Inc.
as 07-26-2024 4:00pm EST
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology and acute respiratory distress syndrome (ARDS). The company is also in the late stage development of certain drugs for management of breast and prostate cancers. It also has a sexual health program which includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in single segment and generates revenue from USA which is the key revenue generating market, South Africa and other regions.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | MIAMI |
| Market Cap: | 138.6M | IPO Year: | 1990 |
| Target Price: | $4.00 | AVG Volume (30 days): | 2.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.34 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.36 - $1.92 | Next Earning Date: | 08-08-2024 |
| Revenue: | $13,479,224 | Revenue Growth: | -36.67% |
| Revenue Growth (this year): | -16.54% | Revenue Growth (next year): | -10.31% |
Stock Insider Trading Activity of Veru Inc. (VERU)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| FISCH HARRY | VERU | Chief Corporate Officer | May 24 '24 | Buy | $1.25 | 4,000 | $5,000.00 | 774,736 | SEC Form 4 |
| BARNETTE K GARY | VERU | Chief Scientific Officer | May 24 '24 | Buy | $1.34 | 5,000 | $6,696.50 | 5,000 | SEC Form 4 |
| STEINER MITCHELL SHUSTER | VERU | President and CEO | May 22 '24 | Sell | $1.39 | 6,504 | $9,018.45 | 7,006,388 | SEC Form 4 |
| STEINER MITCHELL SHUSTER | VERU | President and CEO | May 22 '24 | Sell | $1.35 | 300 | $405.00 | 7,006,088 | SEC Form 4 |
| STEINER MITCHELL SHUSTER | VERU | President and CEO | May 22 '24 | Sell | $1.23 | 63,379 | $78,101.94 | 6,942,709 | SEC Form 4 |
| FISCH HARRY | VERU | Chief Corporate Officer | May 15 '24 | Buy | $1.49 | 6,711 | $9,999.39 | 770,736 | SEC Form 4 |
| STEINER MITCHELL SHUSTER | VERU | President and CEO | May 15 '24 | Sell | $1.50 | 84,021 | $125,813.05 | 7,100,746 | SEC Form 4 |
| STEINER MITCHELL SHUSTER | VERU | President and CEO | May 15 '24 | Sell | $1.41 | 59,788 | $84,127.69 | 7,040,958 | SEC Form 4 |
| STEINER MITCHELL SHUSTER | VERU | President and CEO | May 15 '24 | Sell | $1.32 | 28,066 | $36,988.18 | 7,012,892 | SEC Form 4 |
Latest Veru Inc. News
VERU Breaking Stock News: Dive into VERU Ticker-Specific Updates for Smart Investing
GlobeNewswire
24 days ago
Veru to Participate in the Leerink Therapeutics Forum: I&I and Metabolism
Simply Wall St.
25 days ago
Veru (NASDAQ:VERU) investors are sitting on a loss of 89% if they invested three years ago
GlobeNewswire
a month ago
Veru Announces Safety and Body Composition Data from Two Late-Breaker Presentations at the American Diabetes Association's 84th Scientific Sessions
GlobeNewswire
a month ago
Veru Adjourns 2024 Annual Meeting of Shareholders to June 27, 2024
GlobeNewswire
a month ago
Veru Reminds Shareholders to Vote in Advance of Tomorrow’s Deadline for 2024 Annual Meeting of Shareholders
GlobeNewswire
2 months ago
Veru to Present at the American Diabetes Association's 84th Scientific Sessions
Simply Wall St.
2 months ago
Individual investors account for 48% of Veru Inc.'s (NASDAQ:VERU) ownership, while institutions account for 25%
GlobeNewswire
2 months ago
Veru to Present at the Jefferies Global Healthcare Conference
Compare VERU vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VERU Veru Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.